GLP-2 suppresses LPS-induced inflammation in macrophages by inhibiting erk phosphorylation and NF-κB activation

Cellular Physiology and Biochemistry

Volumn 34, Issue 2, 2014, Pages 590-602

  Xie, Shanshan ^a   Liu, Bingrun ^a   Fu, Shoupeng ^a   Wang, Wei ^a   Yin, Yunhou ^b   Li, Nan ^a   Chen, Wei ^a   Liu, Juxiong ^a   Liu, Dianfeng ^a  

^a JILIN UNIVERSITY   (China)

^b GUIZHOU MINZU UNIVERSITY   (China)

Author keywords

ERK; GLP 2; NF B; Pro inflammatory cytokines

Indexed keywords

CYCLOOXYGENASE 2; GLUCAGON LIKE PEPTIDE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA; PRIMER DNA; BETA ACTIN; MITOGEN ACTIVATED PROTEIN KINASE P38;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; IMMUNOMODULATION; INFLAMMATION; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; NUCLEOTIDE SEQUENCE; PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; MACROPHAGE; PROTEIN ANALYSIS; WESTERN BLOTTING;

ANIMALS; BASE SEQUENCE; DNA PRIMERS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GLUCAGON-LIKE PEPTIDE 2; INFLAMMATION; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; NF-KAPPA B; PHOSPHORYLATION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

MURINAE;

EID: 84907300917     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000363025     Document Type: Article

References (50)

1. Gordon S, Taylor PR: Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005;5:953-964.
2. Gordon S: Alternative activation of macrophages. Nat Rev Immunol 2003;3:23-35.
3. Martinez FO, Sica A, Mantovani A, Locati M: Macrophage activation and polarization. Front Biosci 2007;13:453-461.
4. Goerdt S, Politz O, Schledzewski K, Birk R, Gratchev A, Guillot P, Hakiy N, Klemke C-D, Dippel E, Kodelja V: Alternative versus classical activation of macrophages. Pathobiology 2000;67:222-226.
5. Martinez FO, Helming L, Gordon S: Alternative activation of macrophages: An immunologic functional perspective. Annu Rev Immunol 2009;27:451-483.
6. Guha M, Mackman N: Lps induction of gene expression in human monocytes. Cell Signal 2001;13:85-94.
7. Martindale JL, Holbrook NJ: Cellular response to oxidative stress: Signaling for suicide and survival. J Cell Physiol 2002;192:1-15.
8. Ajmonecat M, De Simone R, Nicolini A, Minghetti L: Effects of phosphatidylserine on p38 mitogen activated protein kinase, cyclic amp responding element binding protein and nuclear factor-b activation in resting and activated microglial cells. J Neurochem 2003;84:413-416.
9. Dai J-N, Zong Y, Zhong L-M, Li Y-M, Zhang W, Bian L-G, Ai Q-L, Liu Y-D, Sun J, Lu D: Gastrodin inhibits expression of inducible no synthase, cyclooxygenase-2 and proinflammatory cytokines in cultured lps-stimulated microglia via mapk pathways. PloS one 2011;6:e21891.
10. Buhl T, Thim L, Kofod H, Orskov C, Harling H, Holst JJ: Naturally occurring products of proglucagon 111-160 in the porcine and human small intestine. J Biol Chem 1988;263:8621-8624.
11. Kato Y, Yu D, Schwartz MZ: Glucagonlike peptide-2 enhances small intestinal absorptive function and mucosal mass in vivo. J Pediatr Surg 1999;34:18-21.
12. Brubaker PL, Izzo A, Hill M, Drucker DJ: Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol1997;272:E1050-E1058.
13. Drucker DJ, Erlich P, Asa SL, Brubaker PL: Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A 1996;93:7911-7916.
14. Drucker DJ, Yusta B, Boushey RP, DeForest L, Brubaker PL: Human [gly2] glp-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol 1999;276:G79-G91.
15. Bulut K, Meier J, Ansorge N, Felderbauer P, Schmitz F, Hoffmann P, Schmidt W, Gallwitz B: Glucagon-like peptide 2 improves intestinal wound healing through induction of epithelial cell migration in vitro - evidence for a tgf-mediated effect. Regul Pept 2004;121:137-143.
16. Boushey RP, Yusta B, Drucker DJ: Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol 1999;277:E937-E947.
17. Liu X, Nelson DW, Holst JJ, Ney DM: Synergistic effect of supplemental enteral nutrients and exogenous glucagon-like peptide 2 on intestinal adaptation in a rat model of short bowel syndrome. Am J Clin Nutr 2006;84:1142-1150.
18. Lovshin J, Drucker DJ: New frontiers in the biology of glp-2. Regul Pept2000;90:27-32.
19. Martin G, Beck P, Sigalet D: Gut hormones, and short bowel syndrome: The enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation. World J Gastroenterol 2006;12:4117.
20. Ivory CP, Wallace LE, McCafferty D-M, Sigalet DL: Interleukin-10- independent anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol2008;295:G1202-G1210.
21. Dubé PE, Brubaker PL: Frontiers in glucagon-like peptide-2: Multiple actions, multiple mediators. Am J Physiol Endocrinol Metab 2007;293:E460-E465.
22. Bremholm L, Hornum M, Andersen UB, Hartmann B, Holst JJ, Jeppesen PB: The effect of glucagon-like peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients. Regul Pept 2011;168:32-38.
23. Cheeseman C: Upregulation of sglt-1 transport activity in rat jejunum induced by glp-2 infusion in vivo. Am J Physiol 1997;273:R1965-R1971.
24. L'Heureux M-C, Brubaker PL: Glucagon-like peptide-2 and common therapeutics in a murine model of ulcerative colitis. J Pharmacol Exp Ther 2003;306:347-354.
25. Sigalet DL, Wallace LE, Holst JJ, Martin GR, Kaji T, Tanaka H, Sharkey KA: Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 2007;293:G211-G221.
26. Liu B, Hong J-S: Role of microglia in inflammation-mediated neurodegenerative diseases: Mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 2003;304:1-7.
27. Nam KN, Park Y-M, Jung H-J, Lee JY, Min BD, Park S-U, Jung W-S, Cho K-H, Park J-H, Kang I: Anti-inflammatory effects of crocin and crocetin in rat brain microglial cells. Eur J Pharmacol 2010;648:110-116.
28. Drenth JP, van der Meer JW: The inflammasome-a linebacker of innate defense. N Engl J Med 2006;355:730.
29. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J: Gout-associated uric acid crystals activate the nalp3 inflammasome. Nature 2006;440:237-241.
30. Munroe DG, Gupta AK, Kooshesh F, Vyas TB, Rizkalla G, Wang H, Demchyshyn L, Yang Z-J, Kamboj RK, Chen H: Prototypic g protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci U S A 1999;96:1569-1573.
31. Bhatnagar P, Purvis S, Barron-Casella E, DeBaun MR, Casella JF, Arking DE, Keefer JR: Genome-wide association study identifies genetic variants influencing f-cell levels in sickle-cell patients. J Hum Genet 2011;56:316-323.
32. Yusta B, Huang L, Munroe D, Wolff G, Fantaske R, Sharma S, Demchyshyn L, Asa SL, Drucker DJ: Enteroendocrine localization of glp-2 receptor expression in humans and rodents. Gastroenterology 2000;119:744-755.
33. Jasleen J, Ashley SW, Shimoda N, Zinner MJ, Whang EE: Glucagon-like peptide 2 stimulates intestinal epithelial proliferation in vitro. Dig Dis Sci 2002;47:1135-1140.
34. Jasleen J, Shimoda N, Shen ER, Tavakkolizadeh A, Whang EE, Jacobs DO, Zinner MJ, Ashley SW: Signaling mechanisms of glucagon-like peptide 2-induced intestinal epithelial cell proliferation. J Surg Res 2000;90:13-18.
35. 1 . J Surg Res 2004;121:5-12.
36. Drucker DJ: Glucagon-like peptides: Regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 2003;17:161-171.
37. Brubaker P, Drucker D: Structure-function of the glucagon receptor family of g protein-coupled receptors: The glucagon, gip, glp-1, and glp-2 receptors. Receptors Channels 2002;8:179-188.
38. Fu S-P, Li S-N, Wang J-F, Li Y, Xie S-S, Xue W-J, Liu H-M, Huang B-X, Lv Q-K, Lei L-C: Bhba suppresses lps-induced inflammation in bv-2 cells by inhibiting nf-b activation. Mediators Inflamm 2014;2014
39. Ghosh S, Hayden MS: New regulators of nf-b in inflammation. Nat Rev Immunol 2008;8:837-848.
40. Hayden MS, Ghosh S: Shared principles in nf-b signaling. Cell 2008;132:344-362.
41. Perkins ND: Integrating cell-signalling pathways with nf-b and ikk function. Nat Rev Mol Cell Biol 2007;8:49-62.
42. Huang P, Han J, Hui L: Mapk signaling in inflammation-associated cancer development. Protein Cell 2010;1:218-226.
43. de Heuvel E, Wallace L, Sharkey KA, Sigalet DL: Glucagon-like peptide 2 induces vasoactive intestinal polypeptide expression in enteric neurons via phophatidylinositol 3-kinase-gamma signaling. Am J Physiol Endocrinol Metab 2012;303:E994-1005.
44. Angelone T, Filice E, Quintieri AM, Imbrogno S, Amodio N, Pasqua T, Pellegrino D, Mule F, Cerra MC: Receptor identification and physiological characterisation of glucagon-like peptide-2 in the rat heart. Nutr Metab Cardiovasc Dis : NMCD 2012;22:486-494.
45. Jasleen J, Shimoda N, Shen ER, Tavakkolizadeh A, Whang EE, Jacobs DO, Zinner MJ, Ashley SW: Signaling mechanisms of glucagon-like peptide 2-induced intestinal epithelial cell proliferation. J Surg Res 2000;90:13-18.
46. Yusta B, Somwar R, Wang F, Munroe D, Grinstein S, Klip A, Drucker DJ: Identification of glucagon-like peptide-2 (glp-2)-activated signaling pathways in baby hamster kidney fibroblasts expressing the rat glp-2 receptor. J Biol Chem 1999;274:30459-30467.
47. Lawrence T, Natoli G: Transcriptional regulation of macrophage polarization: Enabling diversity with identity. Nat Rev Immunol 2011;11:750-761.
48. Gautier EL, Shay T, Miller J, Greter M, Jakubzick C, Ivanov S, Helft J, Chow A, Elpek KG, Gordonov S: Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat Immunol 2012;13:1118-1128.
49. Foster SL, Hargreaves DC, Medzhitov R: Gene-specific control of inflammation by tlr-induced chromatin modifications. Nature 2007;447:972-978.
50. Mikita J, Dubourdieu-Cassagno N, Deloire MS, Vekris A, Biran M, Raffard G, Brochet B, Canron M-H, Franconi J-M, Boiziau C: Altered m1/m2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by m2 activated monocyte administration. Mult Scler 2011;17:2-15.